Skip to Main Content

The news Gilead Sciences dropped Monday was so disappointing it irked even the nicest guy in biotech.

Brad Loncar, an investor based in Kansas City whose cancer-focused exchange-traded fund holds Gilead shares, is a Ted Lasso-like font of cheeriness amid bio-Twitter’s angry froth. Yet even he was upset about the way Gilead and its CEO, Dan O’Day, released information about a key study of its breast cancer drug, Trodelvy — without any specific data. In 2020, Gilead had paid $21 billion for the drug and its maker, Immunomedics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment